ImmuneOnco Biopharmaceuticals (Shanghai) Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:R9Z Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
13 Nov 24	Sell€6,625,623	Lapam Capital	Company	6,251,800	€1.06
24 Oct 24	Sell€2,224,725	Shanghai Yongkan Investment Management Co., Ltd.	Company	3,165,000	€0.70
23 Oct 24	Sell€2,787,666	Shanghai Yongkan Investment Management Co., Ltd.	Company	4,061,800	€0.69
21 Oct 24	Sell€1,132,499	Shanghai Yongkan Investment Management Co., Ltd.	Company	1,675,400	€0.68
04 Oct 24	Sell€1,261,673	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	Company	1,432,200	€0.88
02 Oct 24	Sell€1,399,534	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	Company	2,000,000	€0.70
25 Sep 24	Sell€1,439,268	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	Company	2,468,000	€0.58

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of R9Z?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	3,882,465	0.953%
Employee Share Scheme	45,701,100	11.2%
VC/PE Firms	70,547,575	17.3%
Individual Insiders	70,937,830	17.4%
Institutions	83,870,679	20.6%
General Public	132,368,046	32.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.

Top Shareholders

Top 19 shareholders own 67.5% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
17.2%	Tian Wenzhi	70,182,990	€42.0m	0%	no data
11.2%	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. , ESOP	45,701,100	€27.3m	0%	no data
9.4%	Shanghai Yongkan Investment Management Co., Ltd.	38,272,895	€22.9m	-9.59%	no data
7.92%	Lapam Capital	32,274,680	€19.3m	67.6%	12.63%
4.91%	Lyfe Capital	20,014,593	€12.0m	25%	15.6%
3.4%	Greater Bay Area Homeland Investments Limited	13,854,690	€8.3m	0%	95.61%
3.08%	LAV Investment Adviser Limited	12,542,805	€7.5m	0%	10.43%
2.67%	Shanghai Zhangjiang Science&Technology Venture Capital Co., Ltd	10,862,055	€6.5m	0%	32.49%
2.36%	Shanghai Milestone Asset Management Co., Ltd.	9,631,620	€5.8m	0%	7.89%
1.77%	Shanghai Liyi Investment Management Partnership (Limited Partnership)	7,214,085	€4.3m	-50%	3.62%
1.16%	Shanghai Lineng Asset Management Co., Ltd.	4,742,630	€2.8m	0%	13.8%
1.15%	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	4,694,370	€2.8m	-58.4%	0.93%
0.54%	Milestone Asset Management (Cayman) Co., Ltd.	2,185,020	€1.3m	0%	no data
0.42%	Nanjing Xingjian Ruiying Equity Investment Partnership (Limited Partnership)	1,697,445	€1.0m	0%	no data
0.19%	Chen Fei	753,840	€450.9k	-50%	no data
0.072%	Bosera Asset Management Co., Ltd.	291,800	€174.5k	0%	no data
0.0053%	China Asset Management Co. Ltd.	21,431	€12.8k	0%	no data
0.00025%	Yiquan Cheng	1,000	€609.1	0%	no data
0.00015%	E Fund Management Co., Ltd.	600	€365.5	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/15 07:44
End of Day Share Price	2025/01/14 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sean Wu	Morgan Stanley